Company Description
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.
CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.
The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
| Country | United States |
| Founded | 1983 |
| IPO Date | Jan 1, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Geert Kersten |
Contact Details
Address: 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 United States | |
| Phone | 703 506 9460 |
| Website | cel-sci.com |
Stock Details
| Ticker Symbol | CVM |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000725363 |
| CUSIP Number | 150837706 |
| ISIN Number | US1508377066 |
| Employer ID | 84-0916344 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Geert R. Kersten Esq. | Chief Executive and Financial Officer, CAO,Treasurer and Director |
| Patricia B. Prichep | Chief Financial and Operations Officer, Compliance Officer & Corporate Secretary |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer |
| John Cipriano | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 424B5 | Filing |
| May 27, 2026 | RW | Filing |
| May 19, 2026 | RW | Filing |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 424B4 | Prospectus |
| May 11, 2026 | EFFECT | Notice of Effectiveness |
| May 1, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |